Marinus Pharmaceuticals to Participate at Three Upcoming Investor Healthcare Conferences
September 08 2020 - 4:01PM
Business Wire
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical
company dedicated to the development of innovative therapeutics to
treat rare seizure disorders, today announced that management will
present at the Morgan Stanley Virtual Global Healthcare Conference,
H.C Wainwright Virtual Global Investment Conference and Cantor
Virtual Global Healthcare Conference during the week of September
14.
Additional details can be found below:
H.C. Wainwright Virtual Global Investment Conference
Date: Tuesday, September 15 Time: 12:00 noon Eastern Time
Presenter: Ed Smith, Chief Financial Officer, and Dr. Joseph
Hulihan, Chief Medical Officer Link to webcast:
https://wsw.com/webcast/hcw7/register.aspx?conf=hcw7&page=mrns
Morgan Stanley Virtual Global Healthcare Conference Date:
Tuesday, September 15 Time: 1:15 pm Eastern Time Presenter: Dr.
Scott Braunstein, Chief Executive Officer, and Ed Smith, Chief
Financial Officer Link to webcast:
https://morganstanley.webcasts.com/starthere.jsp?ei=1362519&tp_key=5ef6204e02
Cantor Virtual Global Healthcare Conference Date:
Thursday, September 17 Time: 2:00 pm Eastern Time Presenter: Dr.
Scott Braunstein, Chief Executive Officer, and Ed Smith, Chief
Financial Officer Link to webcast:
https://www.webcaster4.com/Webcast/Page/2495/37404
About Marinus Pharmaceuticals
Marinus Pharmaceuticals, Inc. is a pharmaceutical company
dedicated to the development of innovative therapeutics to treat
rare seizure disorders. Ganaxolone is a positive allosteric
modulator of GABAA receptors that acts on a well-characterized
target in the brain known to have anti-seizure, anti-depressant and
anti-anxiety effects.
Ganaxolone is being developed in IV and oral dose forms intended
to maximize therapeutic reach to adult and pediatric patient
populations in both acute and chronic care settings. Marinus has
conducted the first ever Phase 3 pivotal trial in children with
CDKL5 deficiency disorder and is conducting a Phase 2 trial in
tuberous sclerosis complex, as well as a Phase 2 biomarker-driven
proof-of-concept trial in PCDH19-related epilepsy. The company
intends to initiate a Phase 3 trial in status epilepticus. For more
information visit www.marinuspharma.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200908005959/en/
Sasha Damouni Ellis Vice President, Investor Relations &
Corporate Communications Marinus Pharmaceuticals, Inc. 484-253-6792
sdamouni@marinuspharma.com
Marinus Pharmaceuticals (NASDAQ:MRNS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Marinus Pharmaceuticals (NASDAQ:MRNS)
Historical Stock Chart
From Apr 2023 to Apr 2024